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Abstract 
Acute pain is categorized by a length of 3 to 6 months, is directly related to soft 
tissue damage, and gradually resolves as the injured tissues heal. Chronic pain is 
defined as any pain lasting longer than 12 weeks. Over 100 million Americans suffer 
from chronic pain, and the health care costs and productivity losses approach $635 
billion annually (Institute of Medicine Committee on Advancing Pain Research and 
Education, 2011). The lack of clear quality standards for ethical/legal use of opiates, 
the presence of individuals abusing the system, and the lack of updated, and 
involved public policy make finding a doctor willing to treat chronic pain quite 
difficult. During a personal struggle with chronic pain, I participated in a 10-week 
program consisting of education about chronic pain and common treatments, yoga 
and other strengthening and movement-oriented exercises, and recent research on 
chronic pain and corresponding treatments. I learned about many new, alternative 
ways to fix my body, reduce my pain, and help me live a better life. The purpose of 
this project is to bring awareness to the prevalence of chronic pain, the truth about 
current treatments, and education about alternative treatments.   
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Chronic Pain: Physiological Foundations, Psychological Effects, Common 
Treatments, and New Directions 
During June of 2016, I began experiencing debilitating, constant pain 
throughout my lower back. No injuries or accidents seemed to be the cause and 
there was no easily identified reason I should be feeling severe pain. Over the course 
of a few months, I saw multiple doctors concerning my back pain. One suggested 
this was the result of normal aging, despite only being 20 years old. Others simply 
gave me a 2-day prescription of small doses of muscle relaxers.  
Following months of failed attempts to get some pain relief, a doctor finally 
took an x-ray and found that I have a mild case of scoliosis. Scoliosis itself does not 
typically cause pain, but the lack of stability in my spine caused my muscles to take 
the brunt of my hard, physical work and caused me immense pain. Surgery would be 
too risky in my case, as the curve of my spine begins in the lumbar region.  
I was prescribed a long list of prescriptions medications and began opioid 
therapy. Eventually, I was referred to a clinic that worked with chronic pain 
patients. I participated in a 10-week program consisting of education about chronic 
pain and different common treatments, Acceptance and Commitment Therapy 
(ACT), and yoga/other strengthening and movement-oriented exercises. The onset 
of my chronic pain and my journey through treatment made me aware of the 
prevalence of chronic pain in the United States and the efforts in the medical field to 
find adequate treatments for chronic pain. 
 Chronic pain is a pervasive health issue that many people around the world 
experience, which exacts major costs on personal quality of life and society. 
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According to the National Institute on Drug Abuse, over 100 million Americans 
suffer from chronic pain, and the Institute of Medicine Committee on Advancing 
Pain Research and Education report that health care costs and work productivity 
losses approach $635 billion annually (Institute of Medicine, 2011).  
Pain can manifest in many forms and is classified as acute or chronic. Acute 
pain is expected during the recovery period following injury. When pain persists 
longer than 12 weeks and impedes daily function it is referred to as chronic pain. 
Although the source of the pain may be similar, chronic pain states are different 
from acute pain in underlying mechanisms, symptomatology, and treatment 
responses. Recent research on human and animal subjects have shown that the 
brain undergoes structural changes to the reward circuits within the brain when 
experiencing chronic pain, affecting functionality and activity in those sites 
(Navratilova et al., 2016). As pain progresses from acute to chronic, pain sensitivity 
is exacerbated by negative emotional states and comorbidities such as depression, 
anxiety, anhedonia, sleep disturbance, decision-making abnormalities, and suicide 
risk are common (Navratilova et al., 2016). Many researchers have uncovered 
correlations between chronic pain and poor perception of health, lower functional 
capacity, poor social relationships, isolation, financial difficulties, and higher 
healthcare expenses (Butchart et al., 2009; Morasco et al., 2011).  
In addition to the physical pain and comorbid negative affect, many chronic 
pain patients also encounter stigma associated to chronic pain patients. Often 
resulting from cases where medical imaging is unable to locate a specific source of 
the pain, stigma surrounding chronic pain patients is manifest in judgement, blame, 
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or disbelief from health care professionals, the larger community, friends and 
family, and the workplace (Slade et al., 2009). Judgements assuming malingering or 
pursuit of some gain leave chronic pain patients hesitant to seek care, creating an 
additional roadblock to pain relief.  
As the societal costs grow, the motivation to find adequate relief from 
chronic pain is widespread. With the establishment of the “Decade of Pain Control 
and Research” in 2000, the use of opioids to treat pain became more commonplace, 
and opioids continue to be the most common treatment used to treat chronic pain 
(Krashin et al., 2013). This has resulted in a growing epidemic of opioid use in the 
United States and has encouraged research into alternative treatments for chronic 
pain. Psychological methods of cognitive and behavioral therapy have been used to 
treat chronic pain and comorbid affective disorders. In addition, research into 
medical cannabis has added to the progress toward pharmaceutical-free relief of 
chronic pain. Findings suggest that increasing safe access to medical cannabis may 
reduce the growing problematic use of pharmaceutical opiates, and can reduce 
harms associated with addiction (Lucas, 2012).  
While the array of treatment options for chronic pain patients is expanding, 
many of the common treatments for pain are often inadequate in isolation, and 
make it hard to manage comorbid conditions in addition to the source of pain. The 
treatment methods covered are those with the largest bodies of available research. 
Through analysis of the structural brain changes resulting from chronic pain, as well 
as various common treatments, it is clear that the best approach to chronic pain 
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treatment is interdisciplinary, integrating multiple treatment approaches to address 
chronic pain.  
Comorbidity 
Chronic pain can have many possible sources and many different 
manifestations. For many cases, nonmalignant pain originating from soft tissues or 
neuropathy cannot be seen with diagnostic imaging techniques. The lack of 
objective evidence can delegitimize the suffering of the patient: many chronic pain 
patients are labeled as suffering from psychosomatic symptoms (symptoms 
originating from a psychological factor), implying that the physical symptoms are 
not real (Ablin & Buskila, 2012). Portenoy et al. (2004) argue that although pain 
originating exclusively from psychological factors does occur, it is still less prevalent 
than pain associated with body processes that are influenced by psychosocial 
factors and comorbid psychiatric conditions. Attributing pain to psychosomatic 
sources is an incomplete answer without established cause.  
The incorrect attribution of pain to psychosomatic sources is further 
complicated by the actual prevalence of psychological disorders co-occurring with 
chronic pain. Asmundson and Katz (2012) found that among adults from 17 
countries, those with chronic back or neck pain are two or three times more likely to 
have experienced panic disorder, agoraphobia, or social anxiety disorder, and three 
times more likely to have generalized anxiety disorder or post-traumatic stress 
disorder. Depression has also been shown to increase pain intensity and duration, 
as well as negatively affect pain treatment outcomes (Garland et al., 2014). These 
results were corroborated by findings that chronic pain patients with anxiety or 
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depression tend to have more physical symptoms and that, as the quantity of 
symptoms increases, so does the likelihood of an anxiety disorder or depression 
(Kroenke et al., 1994). Gureje et al.  (2001) found this same pattern cross-culturally. 
Chronic pain patients are also three times as likely to experience suicidal ideation as 
compared to the general population (Tang & Crane, 2006). These findings support 
the notion that chronic pain and psychological disorders often co-occur. The 
frequent co-occurrence is likely due to the chronic pain and psychiatric symptoms 
influence one another in a mutually maintaining way, in that the pain exacerbates 
the psychiatric symptoms and the psychiatric symptoms exacerbate the pain, or that 
there is a third variable that acts on both the pain and mental health. These 
possibilities are not mutually exclusive, making it harder to find the true driving 
force. The truth is that the source of chronic pain is much too complex to be 
considered simply psychosomatic. 
The brain is integral to the experience of pain and to responses to pain. 
Neuroimaging has provided a lot of information regarding how pain is processed in 
the brain and the role that psychological disorders play in chronic pain. Navratilova 
and colleagues (2016) used neuroimaging to investigate changes in brain processing 
resulting from chronic pain, hoping to find a link between chronic pain and 
depression, anxiety, anhedonia, sleep disturbance, and risk of suicide. The 
hypothesis that motivation circuits were affected by chronic pain is based on the 
concept that pain is a homeostatic emotion that causes autonomic responses similar 
to other aversive states like hunger or fear.  
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Researchers found that structural and functional changes occur in emotional 
and reward circuitries in the brain and that chronic pain patients often process pain 
in these affective circuits to a greater extent than those suffering from acute pain 
with an ultimate recovery (Navratilova, et al., 2016). The findings highlight that as 
pain persists, emotional circuits in the brain are changed, indicating a link between 
the high incidence of chronic pain patients experiencing comorbid affective 
disorders. Some patients truly do have comorbid psychiatric symptoms, while 
others suffer from chronic widespread pain, yet do not suffer from psychiatric 
symptoms. In individuals that do not experience comorbid psychiatric symptoms, 
their intact mental health seems to be almost protective regarding their general 
condition (Ablin & Baskila, 2012).  
In response to the affirming evidence of the comorbidity of psychological 
disorders and chronic pain, the current literature recognizes that “pain is a complex 
perceptual experience determined by sensory as well as psychological and social 
influences” (Asmundson & Katz, 2009, p. 889). In order to examine the complexities 
of pain and comorbid disorders, a biopsychosocial model is used to better 
understand health and illness through analyzing the complex interactions between 
biological, psychological, and social factors (Gatchel, 2014). The biopsychosocial 
approach asserts that to comprehensively assess a patient’s pain, it is necessary to 
examine the interrelationships between biological changes, psychological well-
being, and sociocultural environment (Gatchel, 2004).  
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Opioid Treatment 
For any pain not managed with over the counter medications such as aspirin, 
ibuprofen, or acetaminophen, the common next option is treatment with opioids. 
According to Bailey and Vowles (2015), “chronic pain is particularly challenging to 
manage when it comes to opioids because most individuals will build tolerance to 
the drug and any reduction in use is likely to produce withdrawal symptoms 
(indicating dependence)” (p. 342). This creates the potential for significant 
increases in opioid dependence based on predictions that the prevalence of chronic 
pain will grow as the population ages.  
The growth of opioid treatment began when President Clinton signed a law 
dedicating the decade from 2000 to 2010 the “Decade of Pain Control and Research” 
(Lippe, 2000). This decade saw the inclusion of pain as a vital sign and contributed 
to a major increase in the use of opioid treatment resulting from a strong moral 
argument to treat all chronic pain with opioids when other treatments failed to 
provide adequate relief (Krashin et al., 2013). Many efficacy trials indicated that 
opioid treatment is useful in reducing the intensity of neuropathic, nociceptive, and 
musculoskeletal pain experience over a period of 6 months or less. This combination 
of factors led to a rise in opioid prescriptions, as well as the prevalence of opioid 
misuse, with misuse being defined as “use of a medication (for a medical purpose) 
other than as directed or indicated, whether willful or unintentional, and whether 
harm results or not” (Denisco et al., 2008). While the number of cases of opioid 
misuse has leveled off in the past several years, the 2006 National Survey of Drug 
Use and Health (NSDUH) shows increasing mortality associated with opioids, 
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resulting from the increased availability of the medications, rather than misuse by 
those prescribed them (SAMHSA, 2007). The NSDUH reports that 55.7% of those 
who misused opioids said they received the medication from friends or family, and 
that 80.7% reported that the friend or relative had obtained the opioids from one 
doctor. Only 3.9% of respondents reported obtaining the drug from a drug dealer or 
stranger, and 0.1% reported buying the drug from the Internet.  
Chronic pain patients typically respond well to opioids initially, but regular 
use is associated with long term complications including dependence, addiction, and 
withdrawal. The DSM-V (APA, 2013) defines substance dependence as a 
combination of three or more of the following symptoms within a 12-month period: 
tolerance to the effects of a substance, withdrawal upon abrupt cessation, using 
larger amounts than intended, spending a great deal of time on the substance, 
limiting social, occupational, or recreational activities because of substance use, and 
use despite psychological or physical problems from the substance. The American 
Pain Society (2002) defined addiction as one or more of the following symptoms: 
impaired control regarding the use of the drug, compulsive drug use, continued drug 
use despite consequences, and unmanageable drug craving.  
According to the Center for Disease Control and Prevention, in 2014 
approximately 2 million Americans abused or were dependent on prescription 
opioids. In 2016 a total of 42,249 individuals died of opioid overdose, approximately 
115 individuals each day (CDC, 2017). Of the long-term users of prescription opioids 
for chronic pain, the CDC reports that as many as 25% struggle with addiction. The 
risk of dependence or death, coupled with the short-term success of opioid 
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treatment, creates a dilemma for chronic pain patients and medical providers alike. 
In the interest of safety, opioids began to be viewed as a form of comfort care for 
patients who have exhausted all other treatment options and the prospect of 
recovery (Krashin et al., 2013).  
While the use of opioids can be costly on an individual basis, resulting in 
addiction or dependence, the costs to the larger society are a close rival. According 
to Birnbaum and colleagues (2011), workplace, health care, and criminal justice 
costs totaled $55.7 billion in 2007. Workplace costs manifest in lost productivity, 
premature death, lost wages/employment, presenteeism, and absenteeism. In 2007 
the workplace costs totaled $25.6 billion, which is 46% of total societal costs. Health 
care costs accounted for $25 billion, which consisted mainly of excess medical and 
prescription costs. Criminal justice costs occurred in the form of correctional 
facilities and police costs, totaling $5.1 billion (Birnbaum et al., 2011).   
Ballantyne and Shin (2008) found that opioid treatment beyond three 
months is not associated with sustained improvement in pain or function for most 
patients, and that opioids are actually associated with worse functional and 
occupational outcomes in cases of musculoskeletal pain. The collective findings that 
addiction, overdose, and prescription diversion (medications not being taken by the 
person prescribed them, often sold or given to others) are common results of opioid 
therapy left the medical field and public policy makers struggling to address chronic 
pain patients. The major challenge is to minimize the likelihood of opioid misuse, 
without limiting the legitimate use of opioid medications. Attempts to control abuse 
can result in discouraging treatment and restricting the medical profession 
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(Rosenblum et al., 2008). Hesitancy to prescribe opioids also results from the 
perceived and real risks of legal scrutiny regarding the prescribing of a controlled 
substance (Rosenblum et al., 2008). 
The current solution to the dilemma regarding opioid treatment is to identify 
individuals who are at a higher risk of abuse, allowing those with low risk to receive 
the medication while protecting those who are at high risk of addiction. A majority 
of chronic pain patients who are exposed to chronic opioid analgesic therapy will 
not develop addiction or abusive behaviors (3.27%, compared to 10% in the general 
population), while the prevalence of patients who will demonstrate aberrant drug-
related behaviors (including not having prescribed medicines in urine, having 
unprescribed drugs in urine, or other behaviors indicating abuse of or diversion of 
opioids) is higher (11.5%) (Fishbain et al., 2008). If chronic pain patients are 
screened for current or past history of alcohol or illicit drug use, abuse, or addiction, 
the percentage of chronic pain patients misusing opioids is much lower (3.27% in 
non-selected groups, as opposed to 0.19% in preselected groups) (Fishbain et al., 
2008). These findings highlight that the concept of de novo addiction (addiction 
without a previous history of addiction) is rare with chronic opioid analgesic 
therapy.  
While evidence does support the efficacy of opioid treatment, it is important 
to be aware that the results indicate short term success, and do not highlight long-
term risks. It is also important to note that studies regarding opioid therapy lacked 
inclusion of a control group given a placebo, a control with no opioid therapy, or a 
control using a different, nonopioid therapy (Dowell et al., 2016). For this reason, 
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opioid prescription should not be considered the gold standard. Treatment for 
chronic pain should include other psychosocial interventions and possibly other 
physical treatments to target the pain from multiple sides of the biopsychosocial 
framework (Bailey & Vowles, 2015). Dowell et al. (2016) compiled a list of 
recommendations regarding treatment of chronic pain including beginning with 
nonpharmacological therapy or nonopioid pharmacologic therapy, establishing 
treatment goals for pain and function, evaluating benefits and harms with the 
patient, when beginning opioid therapy, begin with the lowest effective dose, and 
considering periodic urine drug testing to assess possible misuse or diversion of 
medications. In addition to these recommendations, multidisciplinary therapies can 
help reduce pain and improve function more effectively than single modality 
treatments (Dowell et al., 2016).  
Medical Use of Cannabis 
Beginning in 2015 the legalization of medical marijuana has swept across the 
United States (Hill, 2015). Legalization facilitates access to marijuana as a treatment 
for a variety of medical conditions. Medical marijuana has also been decriminalized 
in Washington, Colorado, Alaska, Oregon, and Washington D.C. Meanwhile, 
marijuana is still federally illegal: the U.S. Drug Enforcement Administration states 
that until the FDA approves its use, cannabis is not considered a legitimate 
medication. The DEA considers marijuana to be a precursor to abuse of other drugs, 
and to be a danger to the user and to others. This is countered by research that 
shows it is not cannabis itself that leads to further drug use, but rather the 
combination of family history/predisposition to psychoactive substance use, early 
  
CHRONIC PAIN         15 
introduction to cannabis, more rapid progress towards regular use, frequenting 
deviant environments, and availability of various substances from the same dealers 
(Lucas, 2012). Despite arguments for or against its use, marijuana is the most 
commonly used illicit drug in the United States, with 12% of people aged 12 years or 
older reporting use in the last year. A declining perception of risk associated with 
the spread of legalization has increased rates of use among teens (Hill, 2015).  
While differentiated in name, medical and recreational marijuana are 
identical in form. Both are dried material from the Cannabis plant, consisting of 
tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids (Hill, 
2015). In contrast to THC, the psychoactive component of marijuana, CBD does not 
involve the reward center in the brain, and has limited misuse or diversion 
potential. CBD also has very low risks of causing mortality, reducing concerns 
regarding potential overdose (Hurd, 2017). Human and animal studies show that 
CBD can moderate anxiety via activation of the amygdala during negative emotional 
processing (Hurd, 2017).  
Medical marijuana is purchased from dispensaries in a variety of 
preparations or grown by patients or licensed growers (because of its status as 
federally illegal, medical marijuana cannot be obtained in pharmacies). 
Cannabinoids can be administered orally, sublingually, or topically, smoked, inhaled, 
mixed with food, or made into tea. Prescribed cannabinoids come in the form of 
dronabinol capsules, nabilone capsules, and oromucosal spray nabiximols (Whiting 
et al., 2015).  
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Medical marijuana is commonly used to mitigate nausea and vomiting due to 
chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to 
multiple sclerosis, depression, anxiety disorder, sleep disorder, psychosis, 
intraocular pressure in glaucoma, and Tourette syndrome (Whiting et al., 2015). The 
efficacy of medical marijuana varies widely by affliction, but shows high efficacy for 
chronic pain, neuropathic pain, and spasticity due to multiple sclerosis (Hill, 2015). 
Compared with placebo, cannabinoids are associated with greater reduction in pain 
and a greater average reduction in numerical rating pain assessment (Whiting et al., 
2015). The average number of patients who reported a reduction in pain of at least 
30% was also greater with cannabinoids than with placebo, with smoking having 
the greatest beneficial effect. Comparisons of low THC cannabis and high THC 
cannabis report that both methods are effective at reducing pain, with no clear 
correlation between dose levels and pain relief (Lucas, 2012).  
 Common adverse reactions to marijuana use include asthenia, balance 
problems, confusion, dizziness, diarrhea, dry mouth, nausea, fatigue, euphoria, 
vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucinations 
(Whiting et al., 2015). Marijuana also impairs short-term memory, motor 
coordination, and judgement, which double the risk of involvement in a motor 
vehicle crash while driving (Hill, 2015). Paranoid ideation and psychotic symptoms 
are rare, but can occur. Recent studies have found that occasional marijuana users 
undergo structural brain changes in the nucleus accumbens and the amygdala. In 
people younger than 20, brain development can be impaired, with regular 
marijuana use affecting functional connectivity and possibly declining IQ. Regular 
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marijuana use can also produce physical problems, including increased incidence of 
chronic bronchitis, increase rates of respiratory tract infections and pneumonia. 
There is also a potential link between regular marijuana use and heart attack, 
stroke, and peripheral vascular disease. Before beginning medical marijuana, 
patients should have exhausted other treatment options, and have no history of 
substance use disorder, psychotic disorder, unstable mood disorder, or anxiety 
disorder. Patients with conditions such as major depressive disorder, anxiety 
disorders, and viral upper respiratory tract infections may find that marijuana use 
exacerbates these conditions (Hill, 2015). Marijuana use comes with its own risks to 
assess, which must be balanced with potential medical benefits. 
 The typical adverse effects of marijuana use may be outweighed by its 
medical potential to treat many pain manifestations, and its potential benefits to 
reducing opioid dependence and deaths. When used in conjunction with opiates, 
cannabinoids can lead to a greater cumulative relief of pain, which can result in a 
reduction in the use of opiate and associated side effects (Cichewicz et al., 1999). 
Multiple studies indicate that cannabinoid receptors may interrupt signaling in the 
opioid receptor systems, affecting craving for opiates and withdrawal severity 
(Lucas, 2012). States with legalized marijuana laws have reported a reduction in 
opioid use as evidenced by lower number of prescription opioid painkillers, reduced 
number of opioid overdoses, and lower opioid-positive screens associated with car 
fatalities (Hurd, 2017). The resulting public health benefits from reductions in 
opioid use and treatment of chronic pain could include lower rates of alcohol-
related automobile accidents, reduced domestic violence, reductions in drug-related 
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crimes, and reduced drug and alcohol-related morbidity and mortality (Lucas, 
2012). Further than having an impact on patient pain levels and overall quality of 
life, medical marijuana has the potential to reduce overall morbidity and mortality 
associated with pharmaceutical opiates and opioid addiction.  
Acceptance and Commitment Therapy 
Chronic diseases and long-term conditions such as diabetes, HIV, cancer, or 
brain injury have a detrimental effect on quality of life, mood, and overall well-
being. This similarity indicates that well-being is affected by factors that are not 
associated with the specific ailment, but rather perceptions of the illness, coping 
strategies, self-efficacy, psychological flexibility, and emotion regulation (Graham et 
al., 2016). Psychological flexibility is defined as being open, aware, and in contact 
with the present moment, and flexibly engaging in behaviors which facilitate 
overarching life goals. This psychological flexibility involves experiential acceptance, 
contact with the present moment, self-as-context, values, and committed action. 
Distress is considered a normal part of being human, manifest in self-doubt, fear, 
uncertainty, self-criticism, negative thinking, and dysphoria. This is the theoretical 
basis for Acceptance and Commitment Therapy (ACT), a newer form of Cognitive 
Behavior Therapy that see one’s beliefs as the central process involved in therapy. 
ACT does not aim to reduce distress per se, but rather to work through distress and 
focus on values and goals rather than on problems. Individuals are encouraged to 
allow their negative feelings, but try to identify what they can control and make 
changes where they can (Barrett & Chang, 2016). 
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 Research around ACT proliferated in the past decade, and indicates that ACT 
is associated with significant changes in acceptance, values-based action, and 
mindfulness (Scott et al., 2016). As predicted, measures of committed action have 
shown correlation with emotional well-being and general daily functioning (Scott et 
al., 2016). Improvements have also been observed regarding pain, physical and 
social functioning, and depression. Barrett and Chang (2016) found lower 
depression, higher overall improvement ratings, higher pain acceptance, and no 
change in pain severity or disability ratings.  
 While the total number of studies investigating ACT is low, the present 
literature indicates a negative correlation between sample size and effect size, 
meaning that the positive results found could be due to chance and small sample 
sizes (Graham et al., 2016). Publishing bias likely keeps null results from being 
published, furthering possible bias in the overall literature. The subjective nature of 
the qualities that ACT targets require self-report from participants, which could also 
skew results (Scott et al., 2016).  
 The Mid Valley Pain Clinic in Salem, Oregon serves to provide chronic pain 
sufferers with pain management as well as treatment of emotional challenges 
associated with chronic pain, and to educate patients regarding medical and non-
medical resources available to them. Treatment is offered in a 10-week course 
format, where patients meet for a 3-hour session once a week. The 10-week 
program includes a review of medications to assure optimal treatment, pain 
management techniques to improve quality of life, setting goals to move from being 
a chronic pain sufferer to a person living with chronic pain, training in relaxation, 
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movement, coping, and managing pain, education about pain, medication, and 
treatments, and the opportunity to share experiences and support with other 
chronic pain sufferers.   
 Each weekly session begins with 1.5 hours of yoga, breathing, and 
mindfulness exercises. Following movement therapy, the group moves to a 
classroom for education regarding chronic pain and therapeutic activities. Following 
the initial meeting, each week patients are assigned a chapter of reading from Living 
Beyond Your Pain: Using Acceptance and Commitment Therapy to Ease Chronic 
Pain (Dahl & Lundgren, 2006; See Appendix A). 
 The first meeting begins with education regarding the distinction between 
acute and chronic pain and an introduction to mindfulness. Mindfulness requires 
focusing one’s attention on what the individual is experiencing physically, mentally, 
and emotionally in the present moment. The session continues with an overview of 
relaxation techniques (deep, abdominal breathing, progressive muscle relaxation, 
guided imagery, and biofeedback), and posture/body mechanics. The group 
collectively participates in guided imagery led by the instructor, and practice proper 
posture for various everyday situations: driving, cleaning, lifting, and laying down.  
 The second meeting begins with a look at the serenity creed: “Grant me the 
courage to change the things I can, the serenity to accept the things I cannot change, 
and the wisdom to know the difference,” (Dahl & Lundgren, 2006). This is followed 
with an explanation of the “pain chain”: actual physical pain sensation, the mind’s 
reaction to the pain, avoidance or escape behaviors based on the mind’s reaction, 
and long-term choices based on avoidance and escape behaviors (Dahl & Lundgren, 
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2006). Each participant establishes values that are important to them, and learn to 
recognize and halt avoidance behaviors. Instructions for the use of ice and heat 
treatments for pain are provided. A large portion of the meeting focuses on 
communicating with primary care physicians regarding pain treatment, and 
explaining the Pain Patient Bill of Rights (See Appendix B).  
 The third weekly meeting covers information regarding opioid treatment and 
a brief overview of medical marijuana. The opioid treatment portion addresses the 
effects of opiates and common side effects. Patients are informed that long term 
treatment with opiates often requires a material risk notice for controlled 
substances for intractable pain contract between the patient and doctor. 
Distinctions are explored between addiction and dependence, and patients are 
educated regarding aberrant drug-taking behaviors and how to avoid them. 
Education regarding medical marijuana explains that many doctors are governed by 
federal laws, and for this reason many primary care physicians do not condone 
medical marijuana, nor can they prescribe it. The class closes with patients 
considering which values are meaningful to them in their personal lives.  
 The fourth weekly meeting reviews the distinction between dependence and 
addiction, and focuses on values and goals. The class goes over the importance of 
setting goals and how to set achievable goals. With the values determined in the 
previous meeting, patients work through how to turn their aspirations into 
progression toward their personal values. 
 The fifth weekly meeting focuses on the power of thoughts. ACT is built on 
the concept that an individual is not their thoughts (Dahl & Lundgren, 2006). Many 
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patients live with the implicit attitude that they are a person with chronic pain, and 
this concept governs their lives. Cognitive fusion refers to the blurred lines between 
one’s thoughts and one’s sense of self. The group practices observing thoughts and 
separating themselves from their thoughts.  
 The sixth weekly meeting dives deeper into mindfulness. Multiple relaxation 
techniques are employed in an effort to practice mindfulness: repetitive motion, 
word repetition, meditation, guided imagery, and deep breathing. The remainder of 
the class explores the three senses of self that are identified in ACT: the 
conceptualized self, the self as ongoing awareness, and the observer self. The 
conceptualized self is the mentally defined concept an individual has of who they 
are, the self as ongoing awareness refers to one’s sense of personal history, and the 
observer self is always with the individual and will always be (Dahl & Lundgren, 
2006).  
 The seventh weekly meeting addresses acceptance and willingness. 
Acceptance as defined by ACT refers to the act by which one allows oneself to 
willingly engage their pain (Dahl & Lundgren, 2006). Allowing pain to be and 
focusing elsewhere allows one to focus on where they want to be and how to get 
there. The remainder of the class involves imagining common difficult scenarios 
from individual’s lives, and practicing using mindfulness to get through these 
situations.  
 The eighth weekly meeting centers around committed action. Following 
acceptance of pain, one can begin shaping the direction of your life instead of letting 
pain be in control (Dahl & Lundgren, 2006). Acceptance offers a change in 
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perspective, but commitment is required to enact the values that are important to 
the individual. Acceptance allows the individual to recognize that they are in control, 
and commitment is what it takes to get where one wants to be (Dahl & Lundgren, 
2006).  
 The ninth weekly meeting explores alternative treatment methods. 
Treatment methods covered included relaxation therapy, massage therapy, 
chiropractic, aromatherapy, and acupuncture. Contact information is provided for 
local providers of the treatment methods covered.  
 The final weekly session had patients create a unique, comprehensive pain 
plan including as many treatment options as the patient chose from the “Pain 
Management Shopping List”:  
- Guided imagery 
- Distraction 
- Continued group therapy 
- Meditation 
- Relaxation techniques 
- Continue to identify values and goals to reach them 
- Give a hug daily 
- Three deep breaths twice a day 
- Continue to use effective communication techniques with my doctor/build a 
better relationship with my doctor 
- Work on developing good sleep habits 
- Get more exposure to sunlight 
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- Take hot baths/showers 
- Eliminate or decrease alcohol 
- Eliminate or decrease caffeine 
- Eliminate or decrease smoking 
- Explore dietary supplements 
- Work on posture and body position 
- Walk 5 to 15 minutes a day 
- Local anesthetic creams 
- Ice 
- Monitor and treat medication side effects 
- Aromatherapy 
- Pacing 
- Community volunteering 
- Prayer or spirituality 
- Journaling or art 
- Keep a pain log 
- Using touch or vibration 
- Chiropractic 
- Acupuncture 
- Continued individual therapy 
- Maintain healthy body weight 
Following completion of the 10-week program, participants were awarded 
certificates of completion (See Appendix D). 
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Discussion 
Chronic pain can impair work, social, recreational, and household duties. It can have 
a negative impact on financial security, familial, and marital relationships which 
directly affects quality of life. It is clear that treatment is necessary for chronic pain 
sufferers, but the current common treatments are often inadequate in isolation and 
may cause more harm than good.  
 The dramatic increase in opioid misuse and addictions resulting from 
increases in opioid prescriptions shows that opioid treatment is not an adequate 
long-term treatment. Tolerance is quick to develop, and reductions in use produce 
withdrawal symptoms. Even at its best, opioid treatment does not provide true 
relief from all symptoms of chronic pain. As tolerance to the medication increases, 
dosage can only safely increase to a certain degree, ultimately leaving the patient 
with an addiction and without adequate pain relief. In addition, opioids do not 
address the psychosocial issues that are often associated with chronic pain.  
Research into the efficacy of medical marijuana treatment shows potential 
for successfully treating chronic pain, but many questions remain unanswered. 
Research into the medicinal benefits of cannabis is relatively new and the existent 
literature is limited due to a lack of controlled studies. Like opioids, cannabis has 
numerous side effects, though they are likely less dangerous and can be mitigated. 
Side effects such as memory loss, depression, and anxiety responses require further 
investigation into long-term effects.  
The prevalence of studies investigating ACT is constantly growing, but is still 
in its infancy. Compared to other common treatments for common pain, ACT has the 
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fewest potential risks and is the only one to address the psychosocial ailments that 
commonly co-occur with chronic pain. While ACT does address psychosocial factors, 
physical pain relief may also be necessary in some cases. ACT is limited in that 
treatment is expensive, access is limited, and success requires time and commitment 
on the part of the patient. By emphasizing a psychological approach, there is the risk 
of making both patients and physicians believe that pain is “all in their heads,” 
delegitimizing pain. Widespread implementation of ACT would require a cultural 
shift in how pain is perceived and how we think it should be treated.  
 Because chronic pain sufferers are a heterogeneous group, it is clear that 
personalized treatment regimens are needed. This heterogeneity coupled with the 
limits of current treatment methods indicate that the best treatment plan is one that 
is multidisciplinary. Dowell and colleagues (2016) recommend beginning the 
treatment process with nonpharmacological/non-opioid therapy, establishing 
treatment goals for pain level and level of functioning, and beginning with the 
lowest effective dose if opioid therapy is deemed appropriate. Biopsychosocial 
treatment approaches have been shown to improve chronic pain, while targeting all 
sources of distress/pain. While current treatments do show improvements, a 
multidisciplinary treatment is best at quickly and effective reducing the negative 
effects from chronic pain.  
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Appendices 
Appendix A  
 
The 10-week course followed a book written by Joanne Dahl, Living Beyond Your 
Pain: Using Acceptance and Commitment Therapy to Ease Chronic Pain.   
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Appendix B 
 
The 10-week course followed the above syllabus. 
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Appendix C 
 
The Patient Bill of Rights.  
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Appendix D 
 
Upon completion of the course, participants were awarded a certificate of 
completion.  
